Uncategorized
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy
The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.